medigraphic.com

2022, Number 4

<< Back Next >>

Enf Infec Microbiol 2022; 42 (4)

Mpox. An endemic disease in Africa and emerging in the world

Rodríguez NE, González DE, Pérez GHR, Esparza AS, Escobedo SR, Vázquez LM, Aguirre DSA, Morfín OR

Language: Spanish
References: 73
Page: 157-164
PDF size: 169.00 Kb.


ABSTRACT

Monkeypox is a zoonotic disease; before 2022, the infection in humans occurred only in endemic African regions. In April 2022, monkeypox cases began to be reported around the world. The 2022 epidemic is transmitted through skin-to-skin contact and sexual contact. Monkeypox cases in this new epidemic present with fever, lethargy, myalgia, headache, and lymphadenopathy before the appearance of a skin rash. In contrast to previous cases, most patients in 2022 have fewer skin lesions, and a high percentage have anogenital lesions with mucosal lesions. Monkeypox infections are diagnosed using a polymerase chain reaction (PCR). There are antiviral medications active against monkeypox. Tecovirimat is an antiviral that inhibits a crucial protein involved in the viral dissemination and virulence cycle. There is a need for vaccines against orthopox viruses like monkeypox. The replication-deficient, modified vaccine Ankara, JYNNEOS, is used for preexposure exposure of persons at risk for occupational exposure to the virus.


REFERENCES

  1. Titanji, B.K., Tegomoh, B., Nematollahi, S., Konomos, M.y Kulkarni, P.A., “Monkeypox: a contemporary review forhealthcare professionals”, Open Forum Infect Dis, 2022,9: 310.

  2. Shchelkunov, S.N., “An increasing danger of zoonotic orthopoxvirusinfections”, plos Pathog, 2013; 9: e1003756.

  3. Oliveira, G.P., Rodrigues, R.A.L., Lima, M.T., Drumond,B.P. y Abrahao, J.S., “Poxvirus host range genes and virus-host spectrum: a critical review”, Viruses, 2017, 9.

  4. Alakunle, E., Moens, U., Nchinda, G. y Okeke, M.I.,“Monkeypox virus in Nigeria: infection biology, epidemiology,and evolution”, Viruses, 2020, 12.

  5. Reynolds, M.G., Carroll, D.S., Olson, V.A. et al., “A silentenzootic of an orthopoxvirus in Ghana, West Africa:evidence for multi-species involvement in the absenceof widespread human disease”, Am J Trop Med Hyg,2010, 82: 746-754.

  6. Likos, A.M., Sammons, S.A., Olson, V.A. et al., “A tale oftwo clades: monkeypox viruses”, J Gen Virol, 2005, 86:2661-2672.

  7. Chen, N., Li, G., Liszewski, M.K. et al., “Virulence differencesbetween monkeypox virus isolates from WestAfrica and the Congo basin”, Virology, 2005, 340: 46-63.

  8. Forni, D., Molteni, C., Cagliani, R. y Sironi, M., “Geographicstructuring and divergence time frame of monkeypox virusin the endemic región”, J Infect Dis, 2022.

  9. Isidro, J., Borges, V., Pinto, M. et al., “Phylogenomiccharacterization and signs of microevolution in the 2022multi-country outbreak of monkeypox virus”, Nat Med,2022, 28: 1569-1572.

  10. Happi, C., Adetifa, I., Mbala, P. et al., “Urgent need for anon-discriminatory and non-stigmatizing nomenclaturefor monkeypox virus”, plos Biol, 2022, 20: e3001769.

  11. Nuzzo, J.B., Borio, L.L. y Gostin, L.O., “The who Declarationof Monkeypox as a Global Public Health Emergency”,jama, 2022, 328: 615-617.

  12. Von Magnus, P., Andersen, E.K., Petersen, K.B. yBirch-Andersen, A., “A pox-like disease in Cynomegalusmonkeys”, Bull World Health Organ, 1959, 46: 156-176.

  13. Sauer, R.M., Prier, J.E., Buchanan, R.S., Creamer, A.A. yFegley, H.C., “Studies on a pox disease of monkeys. I.Pathology”, Am J Vet Res, 1960, 21: 377-380.

  14. Prier, J.E., Sauer, R.M., Malsberger, R.G. y Sillaman,J.M., “Studies on a pox disease of monkeys. II. Isolationof the etiologic agent”, Am J Vet Res, 1960, 21: 381-384.

  15. Ladnyj, I.D., Ziegler, P. y Kima, E., “A human infectioncaused by monkeypox virus in Basankusu Territory,Democratic Republic of the Congo”, Bull World HealthOrgan, 1972, 46: 593-597.

  16. Marennikova, S.S., Seluhina, E.M., Mal’ceva, N.N.,Cimiskjan, K.L. y Macevic, G.R., “Isolation and propertiesof the causal agent of a new variola-like disease(monkeypox) in man”, Bull World Health Organ, 1972,46: 599-611.

  17. Marennikova, S.S., Seluhina, E.M., Mal’ceva, N.N. yLadnyj, I.D., “Poxviruses isolated from clinically ill andasymptomatically infected monkeys and a chimpanzee”,Bull World Health Organ, 1972, 46: 613-620.

  18. Lourie, B., Bingham, P.G., Evans, H.H., Foster, S.O.,Nakano, J.H. y Herrmann, K.L., “Human infection withmonkeypox virus: laboratory investigation of six casesin West Africa”, Bull World Health Organ, 1972, 46: 633-639.

  19. Foster, S.O., Brink, E.W., Hutchins, D.L. et al., “Humanmonkeypox”, Bull World Health Organ, 1972, 46: 569-576.

  20. Durski, K.N., McCollum, A.M., Nakazawa, Y. et al.,“Emergence of monkeypox: West and Central Africa,1970-2017”, Morb Mortal Wkly Rep, 2018, 67: 306-310.

  21. Jezek, Z., Szczeniowski, M., Paluku, K.M. y Mutombo,M., “Human monkeypox: clinical features of 282 patients”,J Infect Dis, 1987, 156: 293-298.

  22. Jezek, Z., Marennikova, S.S., Mutumbo, M., Nakano,J.H., Paluku, K.M. y Szczeniowski, M., “Humanmonkeypox: a study of 2,510 contacts of 214 patients”,J Infect Dis, 1986, 154: 551-555.

  23. Jezek, Z., Grab, B., Szczeniowski, M.V., Paluku, K.M. yMutombo, M., “Human monkeypox: secondary attackrates”, Bull World Health Organ, 1988, 66: 465-470.

  24. Heymann, D.L., Szczeniowski, M. y Esteves, K.,“Re-emergence of monkeypox in Africa: a review of thepast six years”, Br Med Bull, 1998, 54: 693-702.

  25. Rimoin, A.W., Kisalu, N., Kebela-Ilunga, B. et al., “Endemichuman monkeypox, Democratic Republic of Congo,2001-2004”, Emerg Infect Dis, 2007, 13: 934-937.

  26. Rimoin, A.W., Mulembakani, P.M., Johnston, S.C. etal., “Major increase in human monkeypox incidence 30years after smallpox vaccination campaigns cease inthe Democratic Republic of Congo”, Proc Natl Acad SciUSA, 2010, 107: 16262-16267.

  27. Nolen, L.D., Osadebe, L., Katomba, J. et al., “Introductionof monkeypox into a community and household:risk factors and zoonotic reservoirs in the DemocraticRepublic of the Congo”, Am J Trop Med Hyg, 2015, 93:410-415.

  28. Nolen, L.D., Osadebe, L., Katomba, J. et al., “Extendedhuman-to-human transmission during a monkeypoxoutbreak in the Democratic Republic of the Congo”,Emerg Infect Dis, 2016, 22: 1014-1021.

  29. Yinka-Ogunleye, A., Aruna, O., Ogoina, D. et al., “Reemergenceof human monkeypox in Nigeria, 2017”,Emerg Infect Dis, 2018, 24: 1149-1151.

  30. Yinka-Ogunleye, A., Aruna, O., Dalhat, M. et al., “Outbreakof human monkeypox in Nigeria in 2017-18: aclinical and epidemiological report”, Lancet Infect Dis,2019, 19: 872-879.

  31. Besombes, C., Gonofio, E., Konamna, X. et al., “Intrafamilytransmission of monkeypox virus, Central AfricanRepublic, 2018”, Emerg Infect Dis, 2019, 25: 1602-1604.

  32. Ogoina, D., Iroezindu, M., James, H.I. et al., “Clinicalcourse and outcome of human monkeypox in Nigeria”,Clin Infect Dis, 2020, 71: e210-e214.

  33. Ogoina, D., Izibewule, J.H., Ogunleye, A. et al., “The2017 human monkeypox outbreak in Nigeria: report ofoutbreak experience and response in the Niger DeltaUniversity Teaching Hospital, Bayelsa State, Nigeria”,plos One, 2019, 14: e0214229.

  34. Reed, K.D., Melski, J.W., Graham, M.B. et al., “The detectionof monkeypox in humans in the Western Hemisphere”,N Engl J Med, 2004, 350: 342-350.

  35. Reynolds, M.G., Yorita, K.L., Kuehnert, M.J. et al., “Clinicalmanifestations of human monkeypox influenced byroute of infection”, J Infect Dis, 2006, 194: 773-780.

  36. Reynolds, M.G., Davidson, W.B., Curns, A.T. et al.,“Spectrum of infection and risk factors for humanmonkeypox, United States, 2003”, Emerg Infect Dis,2007, 13: 1332-1339.

  37. Mauldin, M.R., McCollum, A.M., Nakazawa, Y.J. et al.,“Exportation of monkeypox virus from the African Continent”,J Infect Dis, 2022, 225: 1367-1376.

  38. Erez, N., Achdout, H., Milrot, E. et al., “Diagnosis ofimported monkeypox, Israel, 2018”, Emerg Infect Dis,2019, 25: 980-983.

  39. Hobson, G., Adamson, J., Adler, H. et al., “Family clusterof three cases of monkeypox imported from Nigeria tothe United Kingdom, May 2021”, Euro Surveill, 2021, 26.

  40. Minhaj, F.S., Ogale, Y.P., Whitehill, F. et al., “Monkeypoxoutbreak: nine states, May 2022”, Morb Mortal WklyRep, 2022, 71: 764-769.

  41. ÍñigoMartínez, J., Gil Montalbán, E., Jiménez Bueno, S.et al., “Monkeypox outbreak predominantly affectingmen who have sex with men, Madrid, Spain, 26 April to16 June 2022”, Euro Surveill, 2022, 27.

  42. Orviz, E., Negredo, A., Ayerdi, O. et al., “Monkeypoxoutbreak in Madrid (Spain): clinical and virological aspects”,J Infect, 2022.

  43. Peiro-Mestres, A., Fuertes, I., Camprubi-Ferrer, D. et al.,“Frequent detection of monkeypox virus dna in saliva,semen, and other clinical samples from 12 patients,Barcelona, Spain, May to June 2022”, Euro Surveill,2022, 27.

  44. De Nicolás-Ruanes, B., Vivancos, M.J., Azcárraga-Llobet,C. et al., “Monkeypox virus case with maculopapularexanthem and proctitis during the Spanish outbreakin 2022”, J Eur Acad Dermatol Venereol, 2022.

  45. Rodríguez, B.S., Herrador, B.R.G., Franco, A.D. et al.,“Epidemiologic features and control measures duringmonkeypox outbreak, Spain, June 2022”, Emerg InfectDis, 2022, 28.

  46. Tarin-Vicente, E.J., Alemany, A., Agud-Dios, M. et al.,“Clinical presentation and virological assessment ofconfirmed human monkeypox virus cases in Spain: aprospective observational cohort study”, Lancet, 2022,400: 661-669.

  47. Girometti, N., Byrne, R., Bracchi, M. et al., “Demographicand clinical characteristics of confirmed humanmonkeypox virus cases in individuals attending a sexualhealth centre in London, UK: an observational analysis”,Lancet Infect Dis, 2022.

  48. Vivancos, R., Anderson, C., Blomquist, P. et al., “Communitytransmission of monkeypox in the United Kingdom,April to May 2022”, Euro Surveill, 2022, 27.

  49. Pérez Duque, M., Ribeiro, S., Martins, J.V. et al., “Ongoingmonkeypox virus outbreak, Portugal, 29 April to23 May 2022”, Euro Surveill, 2022, 27.

  50. Noe, S., Zange, S., Seilmaier, M. et al., “Clinical and virologicalfeatures of first human monkeypox cases inGermany”, Infection, 2022.

  51. Selb, R., Werber, D., Falkenhorst, G. et al., “A shiftfrom travel-associated cases to autochthonous transmissionwith Berlin as epicentre of the monkeypoxoutbreak in Germany, May to June 2022”, Euro Surveill,2022, 27.

  52. Miura, F., Van Ewijk, C.E., Backer, J.A. et al., “Estimatedincubation period for monkeypox cases confirmed inthe Netherlands, May 2022”, Euro Surveill, 2022, 27.

  53. Antinori, A., Mazzotta, V., Vita, S. et al., “Epidemiological,clinical and virological characteristics of four casesof monkeypox support transmission through sexualcontact, Italy, May 2022”, Euro Surveill, 2022, 27.

  54. Thornhill, J.P., Barkati, S., Walmsley, S. et al., “Monkeypoxvirus infection in humans across 16 countries: April-June2022”, N Engl J Med, 2022.

  55. Vaughan, A., Aarons, E., Astbury, J. et al., “Human-to-humantransmission of monkeypox virus, United Kingdom,October 2018”, Emerg Infect Dis, 2020, 26: 782-785.

  56. Harris, E., “What to know about monkeypox”, jama,2022, 327:2278-2279.

  57. Adler, H., Gould, S., Hine, P. et al., “Clinical features andmanagement of human monkeypox: a retrospectiveobservational study in the UK”, Lancet Infect Dis, 2022.

  58. 58.Aden, T.A., Blevins, P., York, S.W. et al., “Rapid diagnostictesting for response to the monkeypox outbreak: laboratoryresponse network, United States, May 17-June30, 2022”, Morb Mortal Wkly Rep, 2022, 71: 904-907.

  59. Li, D., Wilkins, K., McCollum, A.M. et al., “Evaluation ofthe GeneXpert for human monkeypox diagnosis”, Am JTrop Med Hyg, 2017, 96: 405-410.

  60. Stittelaar, K.J., Neyts, J., Naesens, L. et al., “Antiviraltreatment is more effective than smallpox vaccinationupon lethal monkeypox virus infection”, Nature, 2006,439: 745-748.

  61. Russo, A.T., Grosenbach, D.W., Brasel, T.L. et al.,“Effects of treatment delay on efficacy of tecovirimatfollowing lethal aerosol monkeypox virus challenge inCynomolgus macaques”, J Infect Dis, 2018, 218: 1490-1499.

  62. Grosenbach, D.W., Honeychurch, K., Rose, E.A, et al.,“Oral tecovirimat for the treatment of smallpox”, N EnglJ Med, 2018, 379: 44-53.

  63. Hutson, C.L., Kondas, A.V., Mauldin, M.R. et al., “Pharmacokineticsand efficacy of a potential smallpox therapeutic,brincidofovir, in a lethal monkeypox virus animalmodel”, mSphere, 2021, 6.

  64. Matias, W.R., Koshy, J.M., Nagami, E.H. et al., “Tecovirimatfor the treatment of human monkeypox: an initialseries from Massachusetts, United States”, OpenForum Infect Dis, 2022, 9: ofac377.

  65. Desai, A.N., Thompson, G.R. 3rd, Neumeister, S.M.,Arutyunova, A.M., Trigg, K. y Cohen, S,H., “Compassionateuse of tecovirimat for the treatment of monkeypoxinfection”, jama, 2022.

  66. Frey, S.E., Newman, F.K., Yan, L., Lottenbach, K.R. y Belshe,R.B., “Response to smallpox vaccine in persons immunizedin the distant past”, jama, 2003, 289: 3295-3299.

  67. Sivapalasingam, S., Kennedy, J.S., Borkowsky, W. et al.,“Immunological memory after exposure to variola virus,monkeypox virus, and vaccinia virus”, J Infect Dis, 2007,195: 1151-1159.

  68. Petersen, B.W., Kabamba, J., McCollum, A.M. et al.,“Vaccinating against monkeypox in the Democratic Republicof the Congo”, Antiviral Res, 2019, 162:171-177.

  69. Pittman, P.R., Hahn, M., Lee, H.S. et al., “Phase 3 efficacytrial of modified vaccinia Ankara as a vaccine againstsmallpox”, N Engl J Med, 2019, 381: 1897-1908.

  70. Rao, A.K., Petersen, B.W., Whitehill, F. et al., “Use ofjynneos (smallpox and monkeypox vaccine, live, nonreplicating)for preexposure vaccination of persons at riskfor occupational exposure to orthopoxviruses: recommendationsof the Advisory Committee on ImmunizationPractices: United States, 2022”, Morb Mortal WklyRep, 2022, 71:734-742.

  71. Petersen, E., Zumla, A., Hui, D.S. et al., “Vaccination formonkeypox prevention in persons with high-risk sexualbehaviours to control on-going outbreak of monkeypoxvirus clade 3”, Int J Infect Dis, 2022.

  72. Reynolds, M.G. y Damon, I.K., “Outbreaks of humanmonkeypox after cessation of smallpox vaccination”,Trends Microbiol, 2012, 20: 80-87.

  73. Beer, E.M. y Rao, V.B., “A systematic review of the epidemiologyof human monkeypox outbreaks and implicationsfor outbreak strategy”, plos Negl Trop Dis, 2019,13: e0007791.




2020     |     www.medigraphic.com